Faruqi & Faruqi, LLP Securities Litigation Partner James (Josh) Wilson Encourages Investors Who Suffered Losses In uniQure To Contact Him Directly To Discuss Their Options If you purchased or acquired securities in uniQure between September 24, 2025 and October 31, 2025 and would like to discuss your legal rights, call Faruqi & Faruqi partner Josh Wilson directly at 877-247-4292 or 212-983-9330 (Ext. 1310). [You may also click here for additional information] NEW YORK, Feb. 19, 2026 (GLOBE NEWSWIRE) -- Far ...

NEW YORK, Feb. 19, 2026 (GLOBE NEWSWIRE) -- Bernstein Liebhard LLP, a nationally acclaimed investor rights law firm, reminds uniQure N.V. (“uniQure” or the “Company”) (NASDAQ: QURE) investors of an upcoming deadline involving a securities fraud class action lawsuit commenced against the Company. Should You Join The uniQure Class Action Lawsuit: Do you, or did you, own shares of uniQure N.V. (QURE)?Did you purchase your shares between September 24, 2025 and October 31, 2025, inclusive?Did you lose money in y ...

Core Viewpoint - Kessler Topaz Meltzer & Check, LLP has filed a securities fraud class action lawsuit against uniQure N.V. on behalf of investors who purchased shares between September 24, 2025, and October 31, 2025, alleging material misstatements regarding the company's Huntington's disease gene therapy drug [1]. Group 1: Lawsuit Details - The lawsuit, titled Scocco v. uniQure N.V., was filed in the United States District Court for the Southern District of New York [1]. - The class period for the lawsuit is defined as September 24, 2025, to October 31, 2025, with a deadline for investors to seek lead plaintiff status by April 13, 2026 [1]. - The allegations include misleading statements about the Phase I/II clinical trials of uniQure's leading drug candidate, AMT-130, and the timeline for its Biologics License Application (BLA) submission to the FDA [1]. Group 2: Allegations Against uniQure - The complaint claims that uniQure misrepresented the approval status of the Pivotal Study design by the FDA and downplayed the likelihood of delays in the BLA timeline due to the need for additional studies [1]. - It is alleged that the defendants failed to disclose material adverse facts about uniQure's business and operations, leading to a lack of reasonable basis for their statements regarding the company's prospects [1]. Group 3: Investor Actions - Investors affected by the alleged fraud are encouraged to contact Kessler Topaz Meltzer & Check, LLP for a free case evaluation and to consider filing to be a lead plaintiff by the specified deadline [1]. - The lead plaintiff process allows investors to represent the class in directing the litigation, with the potential for recovery not affected by the decision to serve as lead plaintiff [1].

New York, New York--(Newsfile Corp. - February 18, 2026) - WHY: Rosen Law Firm, a global investor rights law firm, announces a class action lawsuit on behalf of purchasers of ordinary shares of uniQure N.V. (NASDAQ: QURE) between September 24, 2025 and October 31, 2025, inclusive (the "Class Period"). A class action lawsuit has already been filed. If you wish to serve as lead plaintiff, you must move the Court no later than April 13, 2026.SO WHAT: If you purchased uniQure ordinary shares during the Class P ...

NEW YORK, Feb. 18, 2026 (GLOBE NEWSWIRE) -- The Gross Law Firm issues the following notice to shareholders of uniQure N.V. (NASDAQ: QURE). Shareholders who purchased shares of QURE during the class period listed are encouraged to contact the firm regarding possible lead plaintiff appointment. Appointment as lead plaintiff is not required to partake in any recovery. CONTACT US HERE: https://securitiesclasslaw.com/securities/uniqure-loss-submission-form/?id=183603&from=3  CLASS PERIOD: September 24, 2025 to O ...

Philadelphia, Pennsylvania--(Newsfile Corp. - February 18, 2026) - National plaintiffs' law firm Berger Montague PC announces that a class action lawsuit has been filed against uniQure N.V. (NASDAQ: QURE) ("uniQure" or the "Company") on behalf of investors who purchased or otherwise acquired uniQure securities during the period from September 24, 2025 through October 31, 2025 (the "Class Period"). Investor Deadline: Investors who purchased uniQure securities during the Class Period may, no later than Apri ...

Core Viewpoint - Faruqi & Faruqi, LLP is investigating potential claims against uniQure N.V. due to alleged violations of federal securities laws, particularly concerning misleading statements about the company's Pivotal Study and its implications for the BLA submission timeline [2][4]. Group 1: Allegations Against uniQure - The complaint alleges that uniQure and its executives made false and misleading statements regarding the FDA's approval of the Pivotal Study design [4]. - It is claimed that the company downplayed the likelihood of needing to delay its BLA submission due to additional studies required by the FDA [4]. - The statements made by the defendants about the company's business and prospects are said to lack a reasonable basis [4]. Group 2: Impact of Recent Disclosures - On November 3, 2025, uniQure disclosed that the FDA no longer agreed that data from the Phase I/II AMT-130 studies would support a BLA submission, leading to uncertainty about the submission timeline [5]. - Following this announcement, uniQure's share price fell by $33.40, a decline of over 49%, dropping from $67.69 on October 31, 2025, to $34.29 on November 3, 2025 [6]. Group 3: Legal Proceedings - Investors who purchased uniQure securities between September 24, 2025, and October 31, 2025, are encouraged to contact Faruqi & Faruqi to discuss their legal options, with a deadline of April 13, 2026, to seek the role of lead plaintiff in the class action [2][7]. - The lead plaintiff is defined as the investor with the largest financial interest in the relief sought by the class, who will oversee the litigation on behalf of the class members [7]. Group 4: Firm Background - Faruqi & Faruqi, LLP is a national securities law firm with a history of recovering hundreds of millions of dollars for investors since its founding in 1995 [3].

Core Viewpoint - A class action lawsuit has been filed against uniQure N.V. for misrepresentation and failure to disclose critical information regarding its drug candidate for Huntington's Disease, potentially affecting investors who purchased shares during the specified period [1][5]. Group 1: Lawsuit Announcement - Rosen Law Firm has announced a class action lawsuit on behalf of purchasers of uniQure ordinary shares between September 24, 2025, and October 31, 2025 [1]. - Investors who purchased shares during this period may be entitled to compensation without any out-of-pocket fees through a contingency fee arrangement [2]. Group 2: Legal Process and Participation - Interested investors can join the class action by visiting the provided link or contacting the law firm directly [3][6]. - A lead plaintiff must be appointed by April 13, 2026, to represent the class in the litigation [1][3]. Group 3: Details of the Case - The lawsuit alleges that uniQure misrepresented the approval status of its Pivotal Study by the FDA and downplayed the likelihood of delays in its Biologics License Application (BLA) timeline [5]. - The claims suggest that the defendants' statements regarding uniQure's business and prospects lacked a reasonable basis, leading to investor damages when the truth was revealed [5]. Group 4: Law Firm Credentials - Rosen Law Firm has a strong track record in securities class actions, having achieved significant settlements for investors, including over $438 million in 2019 [4]. - The firm has been recognized for its success in securities class action settlements and has a history of representing investors globally [4].

Core Viewpoint - A class action lawsuit has been filed against uniQure N.V. concerning allegations of securities fraud and unlawful business practices [2]. Group 1: Lawsuit Details - The lawsuit involves claims that uniQure and certain officers and/or directors engaged in securities fraud or other unlawful business practices [2]. - Investors have until April 13, 2026, to request to be appointed as Lead Plaintiff if they purchased or acquired uniQure securities during the Class Period [2]. Group 2: Company Developments - On November 3, 2025, uniQure announced feedback from the U.S. FDA regarding its investigational gene therapy AMT-130 for Huntington's disease, indicating a shift in the FDA's stance on the adequacy of data from Phase I/II studies for a Biologics License Application (BLA) submission [4]. - Following this announcement, uniQure's stock price dropped by $33.40 per share, or 49.34%, closing at $34.29 per share on the same day [4].

ATLANTA, Feb. 17, 2026 (GLOBE NEWSWIRE) -- A shareholder class action lawsuit has been filed against uniQure N.V. (“uniQure” or the “Company”) (NASDAQ: QURE). The lawsuit alleges that Defendants issued false and misleading statements and/or failed to disclose material adverse facts regarding uniQure’s business, operations, and prospects, including allegations that: (1) the design of uniQure’s Pivotal Study—including comparison of the Pivotal Study results to the ENROLL-HD external historical data set—was no ...